

Middle East Healthcare (MEH) posted a modest net profit of SAR 10.4mn for Q2-22 (up 14.1%Y/Y, down by a steep 49.1%Q/Q), above our estimates of SAR 7.7mn, but below market consensus of SAR 16.6mn. On a yearly basis- the increase can be attributed to developments in recovering a key client, pricing changes, and a speedy ramp up in utilization at the Dammam Hospital. However, the firm cited the negative seasonal effects of Ramadan and Holidays during Q2-22, which weighed down net profits to a decline from Q1-22. Atop an increase in OPEX, MEH continues to cite the costs of expansions as an overarching variable on the increased costs on net profits- All of which resulted in the continuously lackluster net margin of 2.05% (down 194 bps from Q1-22). We maintain our TP of SAR 30/share and “Neutral” recommendation.

- Middle East Healthcare (MEH) posted a net profit of SAR 10.4mn (up 14.1% Y/Y, down 49.1% Q/Q) in Q2-22, above our estimate of SAR 7.7mn but below consensus estimate of SAR 16.6mn. The Q/Q weak result was attributed to i) the impact of the seasonality of Ramadan and the holidays on the top line ii) a contracting GP margin due to additional cost associated with ongoing expansion iii) increase in OPEX as a natural result of servicing the expansion. This we believe resulted to an EPS at SAR 0.11 (down 50%Q/Q, and up one 0.01 from the same quarter last year). The deviation from our estimates was mainly due to lower-than-expected GP margin.
- The revenues seen by MEH at SAR 508.1mn came at an 11.3%Y/Y increase (down 1.0%Q/Q from SAR 513mn), and below our expectations of SAR 523.7mn. Although revenues were affected by the seasonality of Ramadan and the holidays in Q2, revenues remained buoyant due to increasing service prices, recovering an insurance client, as well as the ramp up in Dammam.
- Gross profits stood at SAR 158.77mn (up 4.0% Y/Y, down 3.8% Q/Q), virtually right in-line with our expectations of SAR 158.5mn. GP margin contracted to 31.2%, below our estimates of 32.3% and 33.4% recorded in Q2-21 (down 218 bps Y/Y) which is possibly due to pressures from the expansion in Jeddah and Asser.
- Operating income, stood at 21.8mn- right by our estimates of SAR 20.4mn (down 38.3% Q/Q, but up 10.8% Y/Y). The figure was pressured by MEH's expansions in Jeddah and Aseer, as well as the increases in marketing and selling costs. OPEX for the quarter amounted to SAR 137mn at 27.0% of revenues- an increase from last quarter's 25.2% OPEX from revenues.

AJC view and valuation: MEH posted a growing top line figure (Y/Y), at a reasonable quarterly decline that was offset by higher prices and utilization in Dammam. However, operational costs remain a pressure on MEH, and especially while they are aggressively expanding. The company's plans to set up new facilities, expand capacity, and enter a joint venture agreement highlights its intention to capture market opportunities. MEH's weak cash generation profile and high leverage position with net debt to TTM EBITDA of 9.4x indicates a point of concern as it balances its expansions and operations. Furthermore, the company's return profile has been the weakest in the sector, with ROE at 1.9% versus the sector average of 13.2% and ROA at 0.6% versus the sector average of 7.6%. MEH's receivable days have been highest after Care at 245 days (FY21). We do believe however that MEH has the business infrastructure to be an attractive company should their financials and cost control return to normality. Until then- We remain “Neutral” on the stock with a TP of SAR 30.0/share.

Results Summary

SARmn	Q2-21	Q1-22	Q2-22	Change Y/Y	Change Q/Q	Deviation from AJC Estimates
Revenue	456.6	513.3	508.1	11.3%	-1.0%	3.3%
Gross Profit	152.6	165.0	158.8	4.0%	-3.8%	0.2%
Gross Margin	33.4%	32.1%	31.2%	-	-	-
EBIT	19.6	35.3	21.8	10.8%	-38.3%	6.8%
Net Profit	9.1	20.5	10.4	14.1%	-49.1%	35.4%
EPS	0.10	0.22	0.11	-	-	-

Source: Company Reports, Aljazira Capital

Neutral

Target Price (SAR) 30.0

Upside / (Downside)* -14.5%

Source: Tadawul *prices as of 07th of August 2022

Key Financials

SARmn (unless specified)	FY20	FY21	FY22E	FY23E
Revenue	1,750.6	1,872.6	2,147.3	2,398.0
Growth %	17.0%	7.0%	14.7%	11.7%
Net Income	82.0	17.2	83.7	99.5
Growth %	-16.0%	-79.0%	386.8%	18.9%
EPS	0.89	0.19	0.91	1.08

Source: Company reports, Aljazira Capital

Key Ratios

	FY20	FY21	FY22E	FY23E
Gross Margin	33.0%	32.5%	32.4%	32.6%
Net Margin	4.7%	0.9%	3.9%	4.2%
P/E (x)	39.3	169.4	36.4	30.7
P/B (x)	2.6	2.3	2.3	2.1
EV/EBITDA (x)	20.8	26.1	16.3	15.1

Source: Company reports, Aljazira Capital

Key Market Data

Market Cap (bn)	3.0bn
YTD %	10.9%
52 Week (High)/(Low)	41.75/30.95
Shares Outstanding (mn)	92.04

Source: Company reports, Aljazira Capital

Price Performance



Source: Tadawul, Aljazira Capital

Equity Analyst

Ibrahim Elaiwat

+966 11 225 6115

i.elaiwat@aljaziracapital.com.sa



RESEARCH DIVISION

Head of Sell-Side Research
Jassim Al-Jubran
+966 11 2256248
j.aljabran@aljaziracapital.com.sa

RESEARCH DIVISION

AlJazira Capital, the investment arm of Bank AlJazira, is a Shariaa Compliant Saudi Closed Joint Stock company and operating under the regulatory supervision of the Capital Market Authority. AlJazira Capital is licensed to conduct securities business in all securities business as authorized by CMA, including dealing, managing, arranging, advisory, and custody. AlJazira Capital is the continuation of a long success story in the Saudi Tadawul market, having occupied the market leadership position for several years. With an objective to maintain its market leadership position, AlJazira Capital is expanding its brokerage capabilities to offer further value-added services, brokerage across MENA and International markets, as well as offering a full suite of securities business.

RATING TERMINOLOGY

1. **Overweight:** This rating implies that the stock is currently trading at a discount to its 12 months price target. Stocks rated "Overweight" will typically provide an upside potential of over 10% from the current price levels over next twelve months.
2. **Underweight:** This rating implies that the stock is currently trading at a premium to its 12 months price target. Stocks rated "Underweight" would typically decline by over 10% from the current price levels over next twelve months.
3. **Neutral:** The rating implies that the stock is trading in the proximate range of its 12 months price target. Stocks rated "Neutral" is expected to stagnate within +/- 10% range from the current price levels over next twelve months.
4. **Suspension of rating or rating on hold (SR/RH):** This basically implies suspension of a rating pending further analysis of a material change in the fundamentals of the company.

Disclaimer

The purpose of producing this report is to present a general view on the company/economic sector/economic subject under research, and not to recommend a buy/sell/hold for any security or any other assets. Based on that, this report does not take into consideration the specific financial position of every investor and/or his/her risk appetite in relation to investing in the security or any other assets, and hence, may not be suitable for all clients depending on their financial position and their ability and willingness to undertake risks. It is advised that every potential investor seek professional advice from several sources concerning investment decision and should study the impact of such decisions on his/her financial/legal/tax position and other concerns before getting into such investments or liquidate them partially or fully. The market of stocks, bonds, macroeconomic or microeconomic variables are of a volatile nature and could witness sudden changes without any prior warning, therefore, the investor in securities or other assets might face some unexpected risks and fluctuations. All the information, views and expectations and fair values or target prices contained in this report have been compiled or arrived at by Al-Jazira Capital from sources believed to be reliable, but Al-Jazira Capital has not independently verified the contents obtained from these sources and such information may be condensed or incomplete. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. Al-Jazira Capital shall not be liable for any loss as that may arise from the use of this report or its contents or otherwise arising in connection therewith. The past performance of any investment is not an indicator of future performance. Any financial projections, fair value estimates or price targets and statements regarding future prospects contained in this document may not be realized. The value of the security or any other assets or the return from them might increase or decrease. Any change in currency rates may have a positive or negative impact on the value/return on the stock or securities mentioned in the report. The investor might get an amount less than the amount invested in some cases. Some stocks or securities maybe, by nature, of low volume/trades or may become like that unexpectedly in special circumstances and this might increase the risk on the investor. Some fees might be levied on some investments in securities. This report has been written by professional employees in Al-Jazira Capital, and they undertake that neither them, nor their wives or children hold positions directly in any listed shares or securities contained in this report during the time of publication of this report, however, The authors and/or their wives/children of this document may own securities in funds open to the public that invest in the securities mentioned in this document as part of a diversified portfolio over which they have no discretion. This report has been produced independently and separately by the Research Division at Al-Jazira Capital and no party (in-house or outside) who might have interest whether direct or indirect have seen the contents of this report before its publishing, except for those whom corporate positions allow them to do so, and/or third-party persons/institutions who signed a non-disclosure agreement with Al-Jazira Capital. Funds managed by Al-Jazira Capital and its subsidiaries for third parties may own the securities that are the subject of this document. Al-Jazira Capital or its subsidiaries may own securities in one or more of the aforementioned companies, and/or indirectly through funds managed by third parties. The Investment Banking division of Al-Jazira Capital maybe in the process of soliciting or executing fee earning mandates for companies that is either the subject of this document or is mentioned in this document. One or more of Al-Jazira Capital board members or executive managers could be also a board member or member of the executive management at the company or companies mentioned in this report, or their associated companies. No part of this report may be reproduced whether inside or outside the Kingdom of Saudi Arabia without the written permission of Al-Jazira Capital. Persons who receive this report should make themselves aware, of and adhere to, any such restrictions. By accepting this report, the recipient agrees to be bound by the foregoing limitations.

Asset Management | Brokerage | Investment Banking | Custody | Advisory

Head Office: King Fahad Road, P.O. Box: 20438, Riyadh 11455, Saudi Arabia. Tel: 011 2256000 - Fax: 011 2256068